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Abstract
In 2014, an acute respiratory illness outbreak affected unaccompanied children from Central 
America entering the United States; 9% of 774 surveyed children were colonized with 
Streptococcus pneumoniae serotype 5. In our 2015 follow-up survey of 475 children, serotype 5 
was not detected, and an interim recommendation to administer 13-valent pneumococcal conjugate 
vaccine to all unaccompanied children was discontinued.
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Unaccompanied children are those <18 years of age who entered the United States without 
legal immigration status and without a parent or legal guardian available to provide care. 
When unaccompanied children from Central America are apprehended by US Customs and 
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Border Protection, they are referred to the Office of Refugee Resettlement (ORR) for 
placement in ORR-funded care provider programs.1 Most children are released to sponsors 
(ie, qualified parents, guardians, relatives or other adults) in the United States.
During June to July 2014, an outbreak of acute respiratory illness affected unaccompanied 
children 9–17 years of age in 4 ORR-funded programs and a centralized processing center, 
preceded by a surge in border crossing that strained the capacity of the US Customs and 
Border Protection and ORR facilities. The illnesses were caused by multiple pathogens, 
including Streptococcus pneumoniae (pneumococcus) serotype 5, which was isolated from 6 
of 14 hospitalized children with blood cultures. A pneumococcal colonization survey 
conducted in July 2014 among nonhospitalized children at the 4 affected programs found 
that serotype 5 was the most frequently isolated serotype [9% (70/774) of surveyed 
children].2 Serotype 5 is rarely isolated in the United States3 but is included in the 13-valent 
pneumococcal conjugate vaccine (PCV13). To aid in controlling transmission of 
pneumococcus, 1 dose of PCV13 was recommended for all unaccompanied children.4 This 
recommendation went beyond the routine US recommendation, which targets children <5 
years of age5 and remained in effect after the outbreak had ceased. In 2015, we conducted a 
follow-up pneumococcal colonization survey to estimate the prevalence of pneumococcal 
serotype 5 colonization among newly arrived unaccompanied children and to determine 
whether continued PCV13 vaccination was still warranted for all unaccompanied children.
METHODS
In August 2015, a cross-sectional survey was conducted at 6 ORR-funded programs in 
Texas. Of the 4 programs surveyed in 2014, only 1 participated in the follow-up survey; the 
other facilities were no longer operating. Thus, additional programs were selected based on 
convenience. Children with or without upper respiratory illness who were not known to have 
active or suspected communicable diseases (eg, varicella, tuberculosis) and had not yet 
received PCV13 or received PCV13 within 72 hours of the survey were eligible.
The survey included nasopharyngeal specimen collection; brief structured interviews to 
assess upper respiratory symptoms and antibiotic exposure; and collection of demographics, 
transit history and PCV13 vaccination history after arrival to the United States from program 
records. We assessed representativeness of the surveyed population compared with children 
referred to ORR-funded programs during Fiscal Year (FY) 2015. This was done by using 
information from a centralized database for unaccompanied children in ORR-funded 
programs from October 1, 2014 (beginning of fiscal year), to August 27, 2015 (end of 
survey period). The 2014 survey methods have been described. Briefly, nasopharyngeal 
swabs and additional data on children’s demographics and transit history were collected 
from assenting nonhospitalized children in the 4 programs.
Laboratory procedures were similar to the 2014 survey. Nasopharyngeal specimens were 
collected from the child’s posterior nasopharynx using flocked swabs, which were 
immediately placed in 1.0 mL skim milk-tryptone-glucose-glycerol transport medium and 
placed in a cooler. Within 4–6 hours, specimens were vortexed and kept at −70°C and 
transported on dry ice to the Streptococcus Laboratory in Atlanta for culture. Supplemented 
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Todd Hewitt broth containing 0.5% yeast extract and 1.0 mL rabbit serum was used for an 
enrichment step followed by subculture onto blood-agar plates.6 Optochin susceptibility and 
bile solubility testing were conducted on any alpha-hemolytic colonies potentially 
identifiable as pneumococcus. If more than 1 potential pneumococcal colony morphology 
was identified per plate, representatives of each colony type were tested. Serotypes were 
obtained by the Quellung reaction. PCV13-serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 
14, 18C, 19A, 19F and 23F) were classified as vaccine type; all other serotypes, including 
nontypeable, were classified as nonvaccine type.
Pneumococcal colonization and serotype distribution were compared with the 2014 results. 
χ2 test or Fisher’s exact test were used for categorical variables. The Brown-Mood median 
test was used for continuous variables. Prevalence ratios with 95% confidence intervals were 
calculated to assess factors associated with vaccine-type colonization.
The survey protocol was reviewed at the Centers for Disease Control and Prevention and 
determined to be part of public health response; therefore, institutional review board review 
was not required. Verbal assent in Spanish was obtained from all included children. Consent 
for participation was obtained from ORR as the temporary custodian of the children.
RESULTS
A total of 495 of 501 (99%) eligible children were enrolled during the 2015 survey; 4 did 
not assent, and 2 declined specimen collection after assent. Compared with unaccompanied 
children referred during FY 2015, surveyed children were more likely to be male [80% 
(397/495) versus 68% (20477/29,960); P < 0.001] and to originate from El Salvador [41% 
(202/495) versus 29% (8697/29960)] and Honduras [25% (126/495) versus 17% 
(5076/29960)] and less likely to originate from Guatemala [34% (165/495) versus 46% 
(13866/29960)]. The demographics of the 2014 survey participants were closer to those of 
children referred during FY 2015 (male 65%, country of origin: El Salvador 27%, Honduras 
26% and Guatemala 46%).
Median age of surveyed children was 16 years (range 7–17), similar to the FY 2015 
population (range 5–17; P = 0.90). Self-reported fever, cough and sore throat were present in 
2%, 14% and 11% of surveyed children, respectively. Antibiotic use within the previous 30 
days was reported by 3% of children.
Of 495 samples collected, 475 (96%) had adequate bacterial growth. Of those, 125 (26%) 
were colonized with pneumococcus, similar to the 2014 survey [24% (185/774); P = 0.30]. 
However, colonization with vaccine-type pneumococci was significantly more prevalent in 
2014 [13% (103/774) of surveyed children] compared with 2015 [6% (28/475); P < 0.0001; 
Fig. 1]. Of serotypes contained in PCV13, serotype 5, the most frequently isolated serotype 
in 2014 [9% (70/774)], was not isolated from any specimens in 2015 (P < 0.0001); vaccine-
type colonization prevalence excluding serotype 5 was similar between the 2 years [4% 
(33/774) in 2014 versus 6% (28/475) in 2015; P = 0.40].
None of the factors reviewed (eg, gender, country of origin, duration of travel, presence of 
upper respiratory symptoms) were associated with prevalence of vaccine-type colonization.
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DISCUSSION
The 2015 colonization survey conducted 1 year after an outbreak of acute respiratory illness 
among unaccompanied children did not detect S. pneumoniae serotype 5, despite serotype 5 
being the most frequently isolated serotype during the 2014 outbreak.
We believe that outbreak control interventions in 2014, which included resolution of 
crowding,2 may have interrupted transmission of serotype 5 among unaccompanied children. 
S. pneumoniae serotype 5 is considered to be one of the most outbreak-prone serotypes 
while being a rare cause of colonization in nonoutbreak settings.7,8 The high prevalence of 
serotype 5 colonization in 2014 was likely because of ongoing transmission during the 
outbreak, whereas the 2015 results are more reflective of baseline (nonoutbreak) serotype 5 
prevalence. Reports from other colonization surveys conducted during and after outbreaks 
have also shown similar patterns. For example, pneumococcal colonization assessments 
conducted among healthy contacts during a serotype 5 pneumococcal pneumonia outbreak 
in a military compound in Israel showed a rapid decrease of serotype 5 colonization from 
24% to less than 1% at 24 days after public health interventions (ie, antibiotic prophylaxis 
and sending the trainees home).9
Our investigation has some limitations. First, the sampling methods used in the 2014 and 
2015 surveys were different: the 2015 survey sampled newly arrived children at ORR-
sponsored facilities, and the 2014 survey was conducted in facilities from which hospitalized 
cases of acute respiratory illness were reported, including 3 temporary facilities that could 
not be included in the 2015 survey. Second, the 2015 survey participants may not be 
representative of the general population of unaccompanied children: compared with children 
referred during FY 2015, males were overrepresented in the 2015 survey and children from 
Guatemala were underrepresented, which might have been a result of our not including 
children entering the United States through Arizona. Historically, Arizona has had the 
second largest number of border crossings after Texas,10 and approximately 80% of children 
apprehended in Arizona and referred to ORR care from October 1, 2014, to August 27, 
2015, were from Guatemala (ORR, unpublished data). However, gender and country of 
origin were not associated with differences in vaccine-type colonization, and serotype 5 was 
not isolated from these subgroups in the 2015 survey. In addition, country of origin was not 
associated with serotype 5 colonization in the 2014 survey.2 Therefore, we believe that our 
survey results can still be used to guide PCV13 policy for the general population of 
unaccompanied children.
The 2015 survey results demonstrated significant reduction in serotype 5 colonization 
prevalence, suggestive of reduced transmission of serotype 5 among newly arrived 
unaccompanied children. Supported by these findings, Centers for Disease Control and 
Prevention recommended discontinuation of the interim recommendation to administer 
PCV13 to all unaccompanied children, with routine PCV13 to continue only for children <5 
years of age. This recommendation was implemented on September 17, 2015.
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FIGURE 1. 
Percentage of nasopharyngeal specimens positive for specific PCV13 serotypes and 
nonvaccine serotypes among unaccompanied children with adequate specimens, by serotype 
and year (n = 774 in 2014, n = 475 in 2015). NVT indicates nonvaccine serotypes. *P < 
0.05.
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